France's Polyplus Transfection announced this week that it has signed a deal to provide its proprietary polyethylenimine, or PEI, transfection reagents to Merck.
Under the deal, Merck acquired the rights to the prior use of PEI for transfection, and Polyplus will supply the drug maker with batches of linear PEI transfection reagent to its sites worldwide.
Financial terms of the arrangement were not disclosed.